News

Drs. Goldstein and Walensky publish a perspective in the NEJM "Where Were the Women? Gender Parity in Clinical Trials"

October 31, 2019

Robert H. Goldstein, M.D., Ph.D., and Rochelle P. Walensky, M.D., M.P.H. explain what happened with the Gilead Sciences DISCOVER trial and why it failed cisgender women and people everywhere.

From the article:
"Two months after its approval for treatment, F/TAF’s manufacturer, Gilead Sciences, moved forward with an effort to expand the drug’s indications to include prevention of HIV infection. To do so, they collaborated with researchers, community members, and the FDA to develop a new preexposure prophylaxis trial protocol — the DISCOVER trial — and to work...

Read more about Drs. Goldstein and Walensky publish a perspective in the NEJM "Where Were the Women? Gender Parity in Clinical Trials"